Chemical Engineering @ChemengFiles.Com

Natural gas has traditionally been carried in pipelines and ships and more recently in subsea pipelines needed to meet growing global demand of oil.

Until the beginning of the century submarine pipelines are the best option for transportation of natural gas when it was little short distances and topographical features. If the distance was greater shipping is preferred by the use of tankers, but this technology is still being developed to achieve a lower environmental impact and lower cost.

A study by the Consejo Superior de Investigaciones Científicas (CSIC) provides new data on the activation of T lymphocytes, a type of white blood cells whose function is crucial for starting the body's immune response against pathogens. The investigation, which is published in the journal Nature Inmunology, reveals a new function of the immunological synapse in this activation process and confirms its importance in the articulation of the immune response.

The activation of T lymphocytes occurs in lymph nodes, regions throughout the human body, which is similar to the meeting points at airports or stations. They bet on other immune system cells of the human body, such as dendritic cells, which have previously engulfed microorganisms in the infection zone, then migrate to the lymph nodes and present antigens to T lymphocytes Through the lymph nodes, T lymphocytes continuously pass feel that dendritic cells to membrane receptors that recognize a TCR specific antigen, which comes from the area of infection, and is exposed on the dendritic cell. When this happens, the cell stops and form immunological synapse with a dendritic cell. This is a complex subcellular structure, formed in the area of interaction between T cells and dendritic cells, which keeps the two cells produced during cell activation. When it happens, the T cells proliferate and leave nodes to participate in the immune response.

Kiadis Pharma has announced that Andrea Velardi, MD, Professor of Clinical Immunology at the University of Perugia (Italy) and Kiadis Pharma will continue their collaboration in ATIR (TM), a product in clinical development to enable the use of a poorly matched donor in a bone marrow transplantation by preventing graft versus host disease (GvHD) in patients with leukemia in the final phase. Under the agreement, Professor Velardi continue development of the selective reduction of donor T cells alorreactivas matched using the wrong product Kiadis Pharma, ATIR (TM). Kiadis Pharma is preparing for a pivotal multicenter study on ATIR (TM) to begin early in 2009 and Professor Velardi participate in this next study.